Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02383329
Other study ID # AUTh112Med
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2015
Est. completion date May 2018

Study information

Verified date November 2018
Source Aristotle University Of Thessaloniki
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test whether the provision of ONS to malnourished children across Europe, in addition to standard counselling, will improve weight gain and other outcomes.

The hypothesis to be tested is:

• Supplementation with ONS in malnourished paediatric patients will lead to increased WFH gain, as well as less malnutrition related complications (e.g. infections).

Primary outcome • The change in BMI z-score over the intervention period of 3 months

Secondary outcomes

• The change in WFH-weight for height (z-scores) over the intervention period of 3 months


Recruitment information / eligibility

Status Completed
Enrollment 224
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender All
Age group 24 Months to 12 Years
Eligibility Inclusion Criteria:

1. Children treated at the participating paediatric centres during the study period (inpatients or outpatients)

2. Age between 24 months to 12 years at inclusion

3. WFH at inclusion <- 1,5 SD - >-2,5 SD (based on WHO) OR Decrease in WFH z-score of =1 SD within the last 3 months, and underlying disease with high risk of undernutrition

4. Children who would be considered candidates for oral nutrition intervention (but do not need tube feeding)

5. Written informed consent of parents/caregivers

Exclusion Criteria:

1. Children in need of intensive care

2. Inability to consume ONS (e.g. major gastrointestinal dysfunction)

3. Children, for whom normal nutrition intervention would be inappropriate (e.g. food intolerance, allergy)

4. Use of parenteral feeding and/or enteral tube-feeding

5. Severe edema (>0.5 cm pitting edema on the dorsum of the foot)

6. Participation in another intervention study involving investigational or marketed products concomitantly or within two weeks prior to entry into the trial.

7. Children having received enteral nutrition treatment for underweight in the previous month

8. Oncology patients during chemo-, radio-therapy

9. Expected hospital stay at inclusion longer than 7 days

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml

Locations

Country Name City State
Belgium UZ Brussel Brussel
Croatia Children's Hospital Zagreb Zagreb
France Hospital Jeanne de Flandre, Pediatrics Department, CHRU Lille
France CHU Tours Tours
Greece Agia Sofia Children's Hospital Athens
Greece 1st Paediatric Dept, Hippokration Hospital, AUTH Thessaloniki
Greece 3rd Paediatric Dept, Hippokration Hospital, AUTH Thessaloniki
Greece Aristotle University of Thessaloniki, School of Medicine Thessaloniki
Iran, Islamic Republic of Mofid Children Hospital Tehran
Iran, Islamic Republic of Tehran University of Medical Sciences Tehran, Children Medical Center Tehran
Norway Department of Pediatrics, Women and Children's Division, Oslo University Hospital Oslo
Poland Medical University of Warsaw Warszawa
Poland The Children's Memorial Health Institute Warszawa
Russian Federation Kazan State Medical University Kazan Respublika Tatarstan
Russian Federation Russian Medical Academy of Postgraduate Education Moscow
Turkey Ankara University School of Medicine Ankara
Turkey Hacettepe University, Ankara Ankara
Turkey Inönü University School of Medicine Inönü
Turkey Dokuz Eylul University, Izmir Inciralti-izmir

Sponsors (15)

Lead Sponsor Collaborator
Dr. Michael Chourdakis Aghia Sophia Children's Hospital of Athens, Children's Hospital Zagreb, Children's Memorial Health Institute, Poland, Dokuz Eylul University, General Hospital Of Thessaloniki Ippokratio, Hacettepe University, Ludwig-Maximilians - University of Munich, Medical University of Warsaw, Oslo University Hospital, Oxford University Hospitals NHS Trust, Russian Medical Academy of Postgraduate Education, Universitair Ziekenhuis Brussel, University Hospital, Lille, University Hospital, Tours

Countries where clinical trial is conducted

Belgium,  Croatia,  France,  Greece,  Iran, Islamic Republic of,  Norway,  Poland,  Russian Federation,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary BMI z-score The change in BMI z-score over the intervention period of 3 months 3 months
Secondary Weight change The change in WFH-weight for height (z-scores) over the intervention period of 3 months 3 months
Secondary Infectious complications Frequency of infectious complications (number of days with temperature >38,5°C, number of infections requiring antibiotic use) 3 months
Secondary Hospital admissions Admission for hospital inpatient treatments (number of days of hospital stay, number of admissions) 3 months
Secondary Gastrointestinal complications Frequency of gastrointestinal complications (number of days with diarrhoea/vomiting as reported by carers). Other GI symptoms could be recorded, as potential reason for lower food intake 3 months